Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.38 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10629728 | 0.89 | MTNR1A (0.44) | TSHRMTNR1AMTNR1BCYP1A2GAA | |
| SCHEMBL9355490 | 0.83 | SMN1; SMN2 (0.45) | ALDH1A1MTNR1AMTNR1BPRKAB2PRKAG1 | |
| SCHEMBL15890439 | 0.83 | PRKAB2 (0.46) | MTNR1AMTNR1BCYP1A2GAACYP2C19 | |
| SCHEMBL11127176 | 0.81 | MTNR1A (0.56) | TSHRALDH1A1MTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL6371042 | 0.81 | TDP1 (0.50) | TDP1TSHRMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL746308 | 0.81 | TDP1 (0.50) | TDP1TSHRMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL10638151 | 0.81 | ESR2 (0.42) | MTNR1AMTNR1BPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL9265587 | 0.81 | ACACB (0.43) | MTNR1AMTNR1BPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL19286562 | 0.81 | TDP1 (0.47) | TDP1TSHRMAPK1ALDH1A1CYP3A4 | |
| SCHEMBL7019275 | 0.81 | MAPT (0.46) | ALDH1A1MTNR1AMTNR1BGAAPRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617799-B2 | Pyrazolopyrimidinone compounds | Orphagen Pharmaceuticals, Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20240208982-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. | 2024-06-27 | — | — | US | disclosed |
| EP-4313988-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117396480-A | Pyrazolopyrimidinone compounds | 奥弗恩制药公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2022204481-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204481-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | Orphagen Pharmaceuticals, Inc. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-03-24 | — | — | US | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| US-20130065879-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8338439-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2519235-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2361248-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| WO-2011090760-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009158571-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS AND USES THEREOF (US) | 2009-12-30 | — | — | WO | disclosed |
| EP-0322643-B1 | MEDICINES CONTAINING AS A MIXTURE INTERFERON AND 1-DESOXY-PIPERIDINOSES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE | BAYER AG (DE) | 1991-07-24 | — | — | EP | disclosed |
| EP-0322643-A1 | Medicines containing as a mixture interferon and 1-desoxy-piperidinoses, process for their manufacture and their use | BAYER AG (DE) | 1989-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | TDP1 2415/4885TSHR 2837/4885MAPK1 4884/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | TDP1 2415/4885TSHR 2837/4885MAPK1 4884/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | TDP1 700/4885TSHR 3159/4885MAPK1 234/4885 |
| US-20130065879-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | TDP1 2415/4885TSHR 2837/4885MAPK1 4884/4885 |
| US-20240208982-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS | CYP2C19, CYP3A4, CYP2C9 | TDP1 2042/4885TSHR 3807/4885MAPK1 4412/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | TDP1 750/4885TSHR 3113/4885MAPK1 106/4885 |
| US-12617799-B2 | Pyrazolopyrimidinone compounds | CYP2B6, CBR1, CYP2D6 | TDP1 3412/4885TSHR 215/4885MAPK1 3298/4885 |
| US-10596172-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | TDP1 700/4885TSHR 3159/4885MAPK1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.